Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29840373 | 1.00 | PCSK9 (0.39) | PCSK9BRD4HDAC10HDAC6BTK | |
| SCHEMBL23303943 | 0.86 | BTK (0.39) | BTKCHRM1 | |
| SCHEMBL27167698 | 0.85 | HDAC6 (0.37) | PCSK9BRD4HDAC10HDAC6BTK | |
| SCHEMBL23336440 | 0.85 | BRD4 (0.42) | PCSK9BRD4BTKAKT1NSD2 | |
| SCHEMBL29840382 | 0.85 | BRD4 (0.42) | PCSK9BRD4BTKAKT1NSD2 | |
| SCHEMBL23336439 | 0.84 | JAK2 (0.42) | BRD4HDAC10HDAC6BTKNSD2 | |
| SCHEMBL29840389 | 0.84 | JAK2 (0.42) | BRD4HDAC10HDAC6BTKNSD2 | |
| SCHEMBL30352426 | 0.83 | RET (0.38) | PCSK9BRD4HDAC10HDAC6BTK | |
| SCHEMBL25574267 | 0.83 | RET (0.38) | PCSK9BRD4HDAC10HDAC6BTK | |
| SCHEMBL25575025 | 0.83 | BRD4 (0.42) | PCSK9BRD4HDAC10HDAC6BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2021087112-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, CDK1, CDK2 | PCSK9 2784/4885BRD4 113/4885HDAC10 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.